skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Assessment of herbal medicinal products: Challenges, and opportunities to increase the knowledge base for safety assessment

Journal Article · · Toxicology and Applied Pharmacology
 [1];  [2]
  1. Marketed Biologicals, Biotechnology and Natural Health Products Bureau, Marketed Health Products Directorate, Health Canada, 200 Tunney's Pasture Driveway, Postal Locator 0701 A, Ottawa, Ontario, K1A 0K9 (Canada)
  2. Bureau of Clinical Trials and Health Sciences, Natural Health Products Directorate, Health Canada (Canada)

Although herbal medicinal products (HMP) have been perceived by the public as relatively low risk, there has been more recognition of the potential risks associated with this type of product as the use of HMPs increases. Potential harm can occur via inherent toxicity of herbs, as well as from contamination, adulteration, plant misidentification, and interactions with other herbal products or pharmaceutical drugs. Regulatory safety assessment for HMPs relies on both the assessment of cases of adverse reactions and the review of published toxicity information. However, the conduct of such an integrated investigation has many challenges in terms of the quantity and quality of information. Adverse reactions are under-reported, product quality may be less than ideal, herbs have a complex composition and there is lack of information on the toxicity of medicinal herbs or their constituents. Nevertheless, opportunities exist to capitalise on newer information to increase the current body of scientific evidence. Novel sources of information are reviewed, such as the use of poison control data to augment adverse reaction information from national pharmacovigilance databases, and the use of more recent toxicological assessment techniques such as predictive toxicology and omics. The integration of all available information can reduce the uncertainty in decision making with respect to herbal medicinal products. The example of Aristolochia and aristolochic acids is used to highlight the challenges related to safety assessment, and the opportunities that exist to more accurately elucidate the toxicity of herbal medicines.

OSTI ID:
21344880
Journal Information:
Toxicology and Applied Pharmacology, Vol. 243, Issue 2; Other Information: DOI: 10.1016/j.taap.2009.12.005; PII: S0041-008X(09)00505-5; Copyright (c) 2009 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; ISSN 0041-008X
Country of Publication:
United States
Language:
English

Similar Records

Risks and benefits of commonly used herbal medicines in Mexico
Journal Article · Fri Feb 15 00:00:00 EST 2008 · Toxicology and Applied Pharmacology · OSTI ID:21344880

Inhibitory effects of herbal constituents on P-glycoprotein in vitro and in vivo: Herb–drug interactions mediated via P-gp
Journal Article · Sat Mar 01 00:00:00 EST 2014 · Toxicology and Applied Pharmacology · OSTI ID:21344880

Priority setting for risk assessment-The benefit of human experience
Journal Article · Thu Sep 01 00:00:00 EDT 2005 · Toxicology and Applied Pharmacology · OSTI ID:21344880